The Patent Finder
BI

Boehringer Ingelheim Pharma GmbH

Filings on record here from 2001, where this site's data begins
OverviewNotableFeesChangesFamiliesPatent listSources & methods

13 patents currently held

120 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
3 more records may belong here and await a decision; they are not counted.

The next term ends in Mar 2027. from the record

Of the 120 now held by other companies, 83 are held via Boehringer Ingelheim International GmbH, and 37 more name another party. Each row says which.

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
7
Ending by 2030
Mar 2027
Next term end
13
Patent families

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
notable patents all others Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Capsule Pharmaceutical Dosage Form Comprising a Suspension Formulation of an Indolinone Derivative US 9,907,756
Cited by 15 later US patents, top 25% of utility patents granted in 2018 in our data, and renewed at every maintenance window due so far. Protection runs to 2029.
Ends Jun 2029 · High confidence
Also notable
Inhaler and sieve for an inhaler US 9,010,323
Renewed at every maintenance window since the 2015 grant; no more fees are due before its term ends in 2030.
Ends Apr 2030 · High confidence
Also notable
Protein Production US 8,221,999
Renewed at every maintenance window since the 2012 grant; no more fees are due before its term ends in 2028.
Ends Apr 2028 · High confidence

Formerly held, still cited

Notable
Cited by 63 later US patents, top 5% of utility patents granted in 2018 in our data, and renewed at every maintenance window due so far. Protection runs to 2034.
held via Boehringer Ingelheim International GmbH - now held by Zealand Pharma A/S
Ends Oct 2034 · High confidence
Also notable
Cited by 18 later US patents, top 10% of utility patents granted in 2021 in our data. Protection runs to 2040.
held via Boehringer Ingelheim International GmbH - now held by Ablynx N.V.
Ends Dec 2040 · High confidence
Also notable
The most cited patent in this portfolio, cited by 67 later US patents, top 25% of utility patents granted in 2006 in our data. Protection runs to 2028.
Ends May 2028 · High confidence

Fee deadlines

No maintenance fee falls due on this company's record before Nov 17, 2027.

Recent changes

  • 3 of the patents on this record were granted since Aug 23, 2026
  • 1 term has ended since Aug 23, 2026

What they patent

The largest of its 13 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.

Patents held now

Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatusExpiresConfidence
US 7,694,676Dry Powder Inhaler
In force
 · High confidence
In forceHigh confidence
US 9,708,626Regulatory Nucleic Acid Elements
In force
 · High confidence
In forceHigh confidence
US 8,221,999Protein Production
In force
 · High confidence
In forceHigh confidence
US 9,907,756Capsule Pharmaceutical Dosage Form Comprising a Suspension Formulation of an Indolinone Derivative
In force
 · High confidence
In forceHigh confidence
US 8,404,674Substituted 9H-PURIN-2-YL Compounds, Compositions Thereof and Uses Thereof
In force
 · High confidence
In forceHigh confidence
US 9,010,323Inhaler and sieve for an inhaler
In force
 · High confidence
In forceHigh confidence
US 8,349,615Method for the Optimization of Chromatographic Purification Processes for Biological Molecules
In force
 · High confidence
In forceHigh confidence
US 10,858,653Mammalian Cells for Producing a Secreted Protein
In force
 · High confidence
In forceHigh confidence
US 10,919,859Benzylaminopyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
In force
 · High confidence
In forceHigh confidence
US 11,324,724Novel N-(2,2-Difluoroethyl)-N-[(PYRIMIDINYLAMINO)PROPANYL]ARYLCARBOXAMIDES
In force
 · High confidence
In forceHigh confidence
10 of 13 patents shown.
Pro members see all 13.
Pro members: see all 13 patents
Also on record, not counted in the 13: 120 patents in force now held by others · 7 patents ended · 97 applications pending · 45 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited